Leaflet EDOFLO 80mcg / 4.5mcg / dose inhalation powder

Indicated for: asthma; chronic obstructive pulmonary disease

Route of administration: inhalation

Substance: budesonide + formoterol (glucocorticoid + beta-2 adrenergic agonist)

ATC: R03AK07 (Respiratory system | Adrenergics, inhalants | Adrenergics in combination with corticosteroids or other drugs, excl. anticholinergics)

Precautions:
Glaucoma warning
Glaucoma warning

Use caution if you have glaucoma or increased eye pressure.

Hyperglycemia
Hyperglycemia

This medicine may increase blood sugar.

Immunosuppression / infection risk
Immunosuppression / infection risk

This medicine may increase the risk of infections.

Breastfeeding warning
Breastfeeding warning

Use during breastfeeding only on medical advice.

Pregnancy warning
Pregnancy warning

Use during pregnancy only on medical advice.

Cardiac risk / QT prolongation / arrhythmias
Cardiac risk / QT prolongation / arrhythmias

This medicine may increase the risk of heart rhythm disturbances.

The combination of budesonide and formoterol is used to treat asthma and chronic obstructive pulmonary disease (COPD). It combines a corticosteroid (budesonide) with a long-acting bronchodilator (formoterol), providing both inflammation control and airway relaxation.

Budesonide reduces airway inflammation, preventing asthma symptoms such as wheezing, coughing, and breathing difficulties. Formoterol acts quickly and long-term to relax airway muscles, making breathing easier and preventing asthma attacks.

This combination is used both as maintenance therapy and, in some cases, for the relief of acute symptoms. It is recommended for patients who require both long-term inflammation control and an effective bronchodilator.

Side effects may include dry mouth, throat irritation, hoarseness, tremors, or palpitations. In rare cases, severe allergic reactions, oral fungal infections (thrush), or worsening respiratory symptoms may occur. It is important for patients to rinse their mouth after using the inhaler to prevent oral infections.

Patients should strictly follow their doctor’s instructions regarding inhaler use. It is essential not to exceed the prescribed dose and to use the medication as part of the treatment plan to prevent asthma or COPD exacerbations.

General data about EDOFLO 80mcg / 4.5mcg / dose

  • Substance: budesonide + formoterol
  • Date of latest medicines list: 01-07-2013
  • Product code: W56421004
  • Concentration: 80mcg / 4.5mcg / dose
  • Pharmaceutical form: inhalation powder
  • Quantity: 10
  • Product type: Original
  • Prescription status: P-6L - Medicines dispensed with a medical prescription that is not retained by the pharmacy and may be renewed; the prescription may be used for 6 months from the date of issue.

Pharmaceutical forms available for budesonide + formoterol

Concentrations available for budesonide + formoterol

  • 160mcg/4.5mcg
  • 160mcg/4.5mcg/dose
  • 320mcg/9mcg
  • 320mcg/9mcg/dose
  • 80mcg/2.25mcg/dose
  • 80mcg/4.5mcg/dose